Health Care [ 10/12 ] | Pharmaceuticals [ 50/74 ]
NASDAQ | Common Stock
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders.
The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds.
It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder.
The company is headquartered in Toronto, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 16, 26 | -1.36 Decreased by -261.69% | -0.98 Decreased by -39.79% |
| Nov 13, 25 | -1.65 Increased by +21.06% | -1.33 Decreased by -24.53% |
| Jul 1, 25 | -0.97 Decreased by -75.31% | -1.10 Increased by +11.98% |
| Mar 31, 25 | -1.46 Decreased by -84.48% | -1.23 Decreased by -18.70% |
| Feb 11, 25 | -0.38 Increased by +85.14% | - |
| Nov 13, 24 | -2.10 Decreased by -45.94% | - |
| Aug 8, 24 | -0.55 Increased by +72.22% | - |
| Jun 25, 24 | -0.79 Increased by +59.73% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 0.00 Decreased by N/A% | -42.63 M Decreased by -293.23% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -47.03 M Increased by +17.34% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -24.61 M Decreased by -127.13% | Decreased by N/A% - |
| Mar 31, 25 | 0.00 Decreased by N/A% | -30.58 M Decreased by -43.25% | Decreased by N/A% - |
| Dec 31, 24 | 0.00 Decreased by N/A% | -10.84 M Increased by +64.25% | Decreased by N/A% - |
| Sep 30, 24 | 0.00 Decreased by N/A% | -56.90 M Decreased by -378.55% | Decreased by N/A% - |
| Jun 30, 24 | N/A Decreased by N/A% | -10.83 M Increased by +25.35% | - - |
| Mar 31, 24 | N/A Decreased by N/A% | -21.35 M Decreased by -55.58% | - - |